Taysha Gene Therapies (TSHA) Return on Capital Employed Growth (1y) (2021 - 2026)
Taysha Gene Therapies (TSHA) Return on Capital Employed Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,042.03 Bn | 67,041.74 Bn | - | 1,648.00 |
| 2 | Nanobiotix | 1,908.00 Bn | 1,907.94 Bn | - | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | 31,429.00 |
| 4 | BeOne Medicines | 471.84 Bn | 467.05 Bn | 1.35 Bn | 1,805.00 |
| 5 | Vertex Pharmaceuticals | 122.13 Bn | 114.88 Bn | 2.59 Bn | 2,503.00 |
| 6 | Regeneron Pharmaceuticals | 70.01 Bn | 61.26 Bn | 3.31 Bn | -105.00 |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn | 2,400.00 |
| 10 | Taysha Gene Therapies | 2.11 Bn | 2.11 Bn | - | 2,590.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2,590.00 |
| Dec 31, 2025 | 2,706.00 |
| Sep 30, 2025 | 2,006.00 |
| Jun 30, 2025 | 1,016.00 |
| Mar 31, 2025 | -526.00 |
| Dec 31, 2024 | -1,437.00 |
| Sep 30, 2024 | -31,810.00 |
| Jun 30, 2024 | 23,681.00 |
| Mar 31, 2024 | 15,290.00 |
| Dec 31, 2023 | 24,055.00 |
| Sep 30, 2023 | 43,230.00 |
| Jun 30, 2023 | -12,668.00 |
| Mar 31, 2023 | -8,246.00 |
| Dec 31, 2022 | -19,107.00 |
| Sep 30, 2022 | -9,715.00 |
| Jun 30, 2022 | -11,528.00 |
| Mar 31, 2022 | -10,503.00 |
| Dec 31, 2021 | -8,217.00 |